Yongbo Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Yongbo Xu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Leilei Luo
Department of Neurology, Tianjin Huanhu Hospital, Tianjin, China
4 shared publications - Shuling Liu
Huanhu Hospital Affiliated to Tianjin Medical University, Tianjin Medical University, China (Y.X., Shuling Liu, X. Jiang, Shuai Liu, K.D., X.Q., X.T., M.W.).
4 shared publications - Ming Wei
Department of Neurosurgery, Tianjin Huanhu Hospital, China (M.W.).
3 shared publications - Sifei Wang
Department of Neurosurgery (Shuling Liu, S.W., X.T., M.W.), Tianjin Huanhu Hospital, China
3 shared publications - Chen Cao
Department of Radiology, Tianjin Huanhu Hospital, Tianjin, China
2 shared publications Shuai Liu
Huanhu Hospital Affiliated to Tianjin Medical University, Tianjin Medical University, China (Y.X., Shuling Liu, X. Jiang, Shuai Liu, K.D., X.Q., X.T., M.W.).
2 shared publications
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2631-2642
Ischemic Postconditioning in Patients With Acute Stroke With Successful Recanalization After Endovascular Therapy: A Pilot Randomized Controlled Trial
BACKGROUND: Ischemia-reperfusion injury contributes to continued infarct growth despite successful recanalization. Ischemic postconditioning (IPostC) reduces infarct size in preclinical models, but its therapeutic effect as an adjunct to endovascular thrombectomy remains uncertain. We investigated whether IPostC performed after successful recanalization reduces infarct growth in patients with acute ischemic stroke. METHODS: This single-center, prospective, randomized, open-label trial with blinded end point assessment was conducted at Tianjin Huanhu Hospital between September 2024 and May 2025. Patients with acute ischemic stroke who underwent endovascular thrombectomy within 24 hours of symptom onset or last known well, had a baseline National Institutes of Health Stroke Scale score ≥6 and a prestroke modified Rankin Scale score ≤2, and achieved successful recanalization after endovascular thrombectomy were randomly assigned to the IPostC or control group. IPostC consisted of 4 cycles of 2-minute balloon inflation followed by 2-minute deflation, with the balloon positioned at the original intracranial arterial occlusion site. The primary outcome was infarct growth from baseline to 48-hour magnetic resonance imaging (MRI). Secondary outcomes included infarct volume on immediate postprocedure MRI (within 2 hours) and on 48-hour MRI; early infarct growth and late infarct growth; serial National Institutes of Health Stroke Scale scores during hospitalization; and modified Rankin Scale score at 90 days. Primary and secondary outcomes were analyzed in the intention-to-treat population using unadjusted between-group comparisons. RESULTS: Sixty patients were enrolled, with 30 randomly assigned to each group. Infarct growth from baseline to 48-hour MRI was lower with IPostC than with control (median difference, −8.7 mL [95% CI, −17.1 to −1.4]; P =0.015). In the serial MRI subgroup (n=30; 15 per group), early infarct growth was also lower with IPostC (median difference, −3.2 mL [95% CI, −8.7 to −0.1]; P =0.045). Patients in the IPostC group had a lower National Institutes of Health Stroke Scale score at 24 hours (median difference, −3.0 [95% CI, −5.0 to −1.0]; P =0.005). The 90-day modified Rankin Scale distribution did not differ significantly between groups (common odds ratio, 1.1 [95% CI, 0.4–2.6]; P =0.921). CONCLUSIONS: In this pilot randomized trial, IPostC performed after successful recanalization reduced infarct growth in patients with acute ischemic stroke due to large-vessel occlusion. These findings require confirmation in larger randomized trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06545734.
- 1 September 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (9) , 2631-2642
Ischemic Postconditioning in Patients With Acute Stroke With Successful Recanalization After Endovascular Therapy: A Pilot Randomized Controlled Trial
BACKGROUND: Ischemia-reperfusion injury contributes to continued infarct growth despite successful recanalization. Ischemic postconditioning (IPostC) reduces infarct size in preclinical models, but its therapeutic effect as an adjunct to endovascular thrombectomy remains uncertain. We investigated whether IPostC performed after successful recanalization reduces infarct growth in patients with acute ischemic stroke. METHODS: This single-center, prospective, randomized, open-label trial with blinded end point assessment was conducted at Tianjin Huanhu Hospital between September 2024 and May 2025. Patients with acute ischemic stroke who underwent endovascular thrombectomy within 24 hours of symptom onset or last known well, had a baseline National Institutes of Health Stroke Scale score ≥6 and a prestroke modified Rankin Scale score ≤2, and achieved successful recanalization after endovascular thrombectomy were randomly assigned to the IPostC or control group. IPostC consisted of 4 cycles of 2-minute balloon inflation followed by 2-minute deflation, with the balloon positioned at the original intracranial arterial occlusion site. The primary outcome was infarct growth from baseline to 48-hour magnetic resonance imaging (MRI). Secondary outcomes included infarct volume on immediate postprocedure MRI (within 2 hours) and on 48-hour MRI; early infarct growth and late infarct growth; serial National Institutes of Health Stroke Scale scores during hospitalization; and modified Rankin Scale score at 90 days. Primary and secondary outcomes were analyzed in the intention-to-treat population using unadjusted between-group comparisons. RESULTS: Sixty patients were enrolled, with 30 randomly assigned to each group. Infarct growth from baseline to 48-hour MRI was lower with IPostC than with control (median difference, −8.7 mL [95% CI, −17.1 to −1.4]; P =0.015). In the serial MRI subgroup (n=30; 15 per group), early infarct growth was also lower with IPostC (median difference, −3.2 mL [95% CI, −8.7 to −0.1]; P =0.045). Patients in the IPostC group had a lower National Institutes of Health Stroke Scale score at 24 hours (median difference, −3.0 [95% CI, −5.0 to −1.0]; P =0.005). The 90-day modified Rankin Scale distribution did not differ significantly between groups (common odds ratio, 1.1 [95% CI, 0.4–2.6]; P =0.921). CONCLUSIONS: In this pilot randomized trial, IPostC performed after successful recanalization reduced infarct growth in patients with acute ischemic stroke due to large-vessel occlusion. These findings require confirmation in larger randomized trials. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06545734.
- 24 December 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (12) , 2263-2270
Intra-arterial albumin following endovascular reperfusion for large vessel occlusion stroke: a prospective cohort study
Background: Preclinical reports suggest that intra-arterial (IA) 20% albumin may have neuroprotective effects. A 3+3 dose-escalation pilot clinical trial preliminarily confirmed the safety and feasibility of doses up to 0.6 g/kg. Based on these findings, we aimed to evaluate the safety and explore the potential efficacy of adjunctive IA albumin in acute ischemic stroke patients undergoing endovascular thrombectomy (EVT). Methods: This prospective single-center cohort trial enrolled patients with successful recanalization (defined as a score on the expanded Thrombolysis In Cerebral Infarction (eTICI) scale of 2b to 3). Patients were classified into the EVT alone group and IA albumin group. The primary endpoint was any intracranial hemorrhage (ICH). Secondary endpoints included pulmonary edema/congestive heart failure, symptomatic ICH, and all-cause mortality within 90 days. Exploratory efficacy endpoints included excellent outcome at 90 days (defined as a modified Rankin Scale score of 0–1), final infarct volume, and glymphatic system activity quantified by diffusion tensor imaging via the ALPS (analysis along the perivascular space) index. Results: We enrolled 251 patients, with 103 in the IA albumin group and 148 in the EVT alone group. After propensity score matching, each group had 103 patients with balanced baseline characteristics. The primary safety outcome of any ICH occurred in 16.5% of the albumin group versus 25.2% of controls, with no statistically significant difference between groups (OR 0.25, 95% CI 0.25 to 1.09, P=0.081). No significant differences were observed in other safety outcomes. In the post hoc exploratory efficacy analyses, the IA albumin group had a greater likelihood of excellent neurological outcome at 90 days, smaller final infarct volumes, and higher ALPS index. Conclusion: In patients with acute large vessel occlusion, adjunctive IA albumin after successful thrombectomy was safe and well-tolerated. In post hoc exploratory analyses, this treatment was associated with a higher likelihood of achieving an excellent neurological outcome at 90 days and with reduced final infarct volume. The neuroprotective effect may be mediated by restoration of glymphatic function. These promising findings warrant validation in multicenter randomized trials.
- 24 December 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (12) , 2263-2270
Intra-arterial albumin following endovascular reperfusion for large vessel occlusion stroke: a prospective cohort study
Background: Preclinical reports suggest that intra-arterial (IA) 20% albumin may have neuroprotective effects. A 3+3 dose-escalation pilot clinical trial preliminarily confirmed the safety and feasibility of doses up to 0.6 g/kg. Based on these findings, we aimed to evaluate the safety and explore the potential efficacy of adjunctive IA albumin in acute ischemic stroke patients undergoing endovascular thrombectomy (EVT). Methods: This prospective single-center cohort trial enrolled patients with successful recanalization (defined as a score on the expanded Thrombolysis In Cerebral Infarction (eTICI) scale of 2b to 3). Patients were classified into the EVT alone group and IA albumin group. The primary endpoint was any intracranial hemorrhage (ICH). Secondary endpoints included pulmonary edema/congestive heart failure, symptomatic ICH, and all-cause mortality within 90 days. Exploratory efficacy endpoints included excellent outcome at 90 days (defined as a modified Rankin Scale score of 0–1), final infarct volume, and glymphatic system activity quantified by diffusion tensor imaging via the ALPS (analysis along the perivascular space) index. Results: We enrolled 251 patients, with 103 in the IA albumin group and 148 in the EVT alone group. After propensity score matching, each group had 103 patients with balanced baseline characteristics. The primary safety outcome of any ICH occurred in 16.5% of the albumin group versus 25.2% of controls, with no statistically significant difference between groups (OR 0.25, 95% CI 0.25 to 1.09, P=0.081). No significant differences were observed in other safety outcomes. In the post hoc exploratory efficacy analyses, the IA albumin group had a greater likelihood of excellent neurological outcome at 90 days, smaller final infarct volumes, and higher ALPS index. Conclusion: In patients with acute large vessel occlusion, adjunctive IA albumin after successful thrombectomy was safe and well-tolerated. In post hoc exploratory analyses, this treatment was associated with a higher likelihood of achieving an excellent neurological outcome at 90 days and with reduced final infarct volume. The neuroprotective effect may be mediated by restoration of glymphatic function. These promising findings warrant validation in multicenter randomized trials.
- 8 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (9) , 1842-1848
Intra-arterial human serum albumin therapy following mechanical thrombectomy for acute ischemic stroke: the AMASS pilot trial
Background Despite successful mechanical thrombectomy (MT), approximately 50% of patients with large vessel occlusion (LVO) stroke experience poor outcomes due to reperfusion injury. Intra-arterial infusion of human serum albumin (HSA) may offer neuroprotective benefits; however, its safety and feasibility have not been established when delivered via the internal carotid artery. In this study we aimed to evaluate the safety and technical feasibility of HSA infusion through the guiding catheter placed during MT in patients with anterior circulation LVO stroke following successful reperfusion. Methods We conducted a prospective, single-center, open-label, pilot trial evaluating intra-arterial infusion of 20% HSA immediately after MT in patients with anterior circulation LVO stroke. The study included a 3+3 dose-escalation and a dose-expansion phase. Eligible patients achieved successful reperfusion (modified Thrombolysis in Cerebral Infarction score ≥2b) and received HSA infusion via the guiding catheter. Safety endpoints included 90-day mortality, symptomatic intracranial hemorrhage (sICH), and serious adverse events. Post-hoc analyses explored infarct volume, immune markers, and proteomic/metabolomic signatures. Results Between September 2023 and February 2024, 42 patients received intra-arterial HSA infusion. In the dose-escalation phase (n=27), two deaths and two mild infusion-related adverse events occurred, with no sICH. In the dose-expansion phase (n=15), one death and one case of sICH were reported, with no HSA-related adverse events. Post-hoc analysis showed that the HSA group had a significantly smaller infarct volume at 24 hours compared with controls. Conclusions Intra-arterial infusion of 20% HSA in combination with MT is safe and feasible. Preliminary findings suggest a potential therapeutic benefit in reducing infarct volume. Trial registration number NCT05953623.
- 8 September 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (9) , 1842-1848
Intra-arterial human serum albumin therapy following mechanical thrombectomy for acute ischemic stroke: the AMASS pilot trial
Background Despite successful mechanical thrombectomy (MT), approximately 50% of patients with large vessel occlusion (LVO) stroke experience poor outcomes due to reperfusion injury. Intra-arterial infusion of human serum albumin (HSA) may offer neuroprotective benefits; however, its safety and feasibility have not been established when delivered via the internal carotid artery. In this study we aimed to evaluate the safety and technical feasibility of HSA infusion through the guiding catheter placed during MT in patients with anterior circulation LVO stroke following successful reperfusion. Methods We conducted a prospective, single-center, open-label, pilot trial evaluating intra-arterial infusion of 20% HSA immediately after MT in patients with anterior circulation LVO stroke. The study included a 3+3 dose-escalation and a dose-expansion phase. Eligible patients achieved successful reperfusion (modified Thrombolysis in Cerebral Infarction score ≥2b) and received HSA infusion via the guiding catheter. Safety endpoints included 90-day mortality, symptomatic intracranial hemorrhage (sICH), and serious adverse events. Post-hoc analyses explored infarct volume, immune markers, and proteomic/metabolomic signatures. Results Between September 2023 and February 2024, 42 patients received intra-arterial HSA infusion. In the dose-escalation phase (n=27), two deaths and two mild infusion-related adverse events occurred, with no sICH. In the dose-expansion phase (n=15), one death and one case of sICH were reported, with no HSA-related adverse events. Post-hoc analysis showed that the HSA group had a significantly smaller infarct volume at 24 hours compared with controls. Conclusions Intra-arterial infusion of 20% HSA in combination with MT is safe and feasible. Preliminary findings suggest a potential therapeutic benefit in reducing infarct volume. Trial registration number NCT05953623.
- 31 August 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (8) , 1757-1764
In situ ischemic postconditioning for acute ischemic stroke: preliminary exploratory study
Background Endovascular therapy within 24 hours of stroke onset is effective and safe, but successful recanalization does not always give favorable outcomes. Ischemic postconditioning (IPostC), a reperfusion strategy with potential neuroprotective effects, has been extensively studied in preclinical models, but its impact in humans remains unclear. Building on a previous dose escalation study, we aimed to investigate the effect of in situ IPostC on infarct volume in patients with acute ischemic stroke following mechanical thrombectomy. Methods This prospective, externally controlled, non-randomized trial compared in situ IPostC (four cycles of 2 min of occlusion/2 min of release) plus thrombectomy with contemporaneous external controls receiving thrombectomy alone. Propensity score matching (PSM) minimized selection bias. The primary outcome was infarct volume at 72 hours post-thrombectomy. Deep infarct volume was also compared in post hoc analyses. Peripheral blood was collected 24 hours post-procedure to assess leukocyte populations, with mononuclear cell subsets characterized by flow cytometry. Serum inflammatory biomarkers were also measured in both groups. Results After 1:1 PSM, 19 patients per group were analyzed. The IPostC group showed significantly less deep infarct volume progression (median 2.3 vs 4.7 mL; P=0.045), lower interleukin 6 levels (median 26.4 vs 32.6 pg/mL; P=0.032), higher Th/CTL ratios (median 2.04 vs 1.65; PConclusions In situ IPostC following thrombectomy for large vessel occlusion stroke may be associated with reduced deep infarct volume progression and favorable immunomodulatory effects, warranting further validation in phase II trials. Trial registration ClinicalTrials.gov NCT05909982.
- 31 August 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (8) , 1757-1764
In situ ischemic postconditioning for acute ischemic stroke: preliminary exploratory study
Background Endovascular therapy within 24 hours of stroke onset is effective and safe, but successful recanalization does not always give favorable outcomes. Ischemic postconditioning (IPostC), a reperfusion strategy with potential neuroprotective effects, has been extensively studied in preclinical models, but its impact in humans remains unclear. Building on a previous dose escalation study, we aimed to investigate the effect of in situ IPostC on infarct volume in patients with acute ischemic stroke following mechanical thrombectomy. Methods This prospective, externally controlled, non-randomized trial compared in situ IPostC (four cycles of 2 min of occlusion/2 min of release) plus thrombectomy with contemporaneous external controls receiving thrombectomy alone. Propensity score matching (PSM) minimized selection bias. The primary outcome was infarct volume at 72 hours post-thrombectomy. Deep infarct volume was also compared in post hoc analyses. Peripheral blood was collected 24 hours post-procedure to assess leukocyte populations, with mononuclear cell subsets characterized by flow cytometry. Serum inflammatory biomarkers were also measured in both groups. Results After 1:1 PSM, 19 patients per group were analyzed. The IPostC group showed significantly less deep infarct volume progression (median 2.3 vs 4.7 mL; P=0.045), lower interleukin 6 levels (median 26.4 vs 32.6 pg/mL; P=0.032), higher Th/CTL ratios (median 2.04 vs 1.65; PConclusions In situ IPostC following thrombectomy for large vessel occlusion stroke may be associated with reduced deep infarct volume progression and favorable immunomodulatory effects, warranting further validation in phase II trials. Trial registration ClinicalTrials.gov NCT05909982.